Table 2 Information on the participants’ experience in the management of patients with chronic immune-mediated inflammatory diseases
All participants | Specialized dentist activitya | General dentist activity | P-valueb | |
|---|---|---|---|---|
N = 115 (%) | N = 54 (%) | N = 61 (%) | ||
Patients with Chronic Rheumatoid Inflammatory Disease (IRDs) | ||||
Yes | 105 (91.30) | 48 (88.89) | 57 (93.40) | 0.38 |
No | 10 (8.70) | 6 (11.11) | 4 (6.50) | |
Patients with Inflammatory Bowel Diseases (IBDs) | ||||
Yes | 101 (87.83) | 46 (85.20) | 55 (90.16) | 0.41 |
No | 14 (12.17) | 8 (14.80) | 6 (9.84) | |
Patients with Vasculitis | ||||
Yes | 72 (62.61) | 37 (68.20) | 35 (57.38) | 0.21 |
No | 43 (37.39) | 17 (32.80) | 26 (42.62) | |
Mean number of patients treated per month (SD) | ||||
With IRDs | 1.51 (1.61) | 1.93 (1.73) | 1.16 (1.42) | 0.99 |
With IBDs | 0.84 (1.09) | 1.10 (1.31) | 0.63 (0.81) | 0.98 |
With vasculitis | 0.39 (0.74) | 0.57 (0.98) | 0.20 (0.24) | 0.98 |
Type of biologics used by patients under carec | ||||
Anti-TNF | 75 (70.09) | 35 (71.42) | 40 (68.96) | 0.28 |
Anti-IL1 | 14 (13.08) | 9 (18.36) | 5 (8.62) | 0.16 |
Anti-IL6 | 22 (20.56) | 13 (26.53) | 9 (15.51) | 0.19 |
Anti-IL12/23 | 10 (9.34) | 6 (12.24) | 4 (6.89) | 0.39 |
Anti-B cells | 36 (33.64) | 22 (44.89) | 14 (24.13) | 0.02 |
Anti-T cells | 15 (14.01) | 10 (20.40) | 5 (8.62) | 0.09 |
Anti-IL17 | 4 (3.73) | 2 (4.08) | 2 (3.44) | 0.90 |
Anti-integrin | 9 (8.44) | 7 (14.28) | 2 (3.44) | 0.05 |
Anti-Jak | 7 (6.62) | 5 (10.20) | 2 (3.44) | 0.18 |
Did not know the name of the drug | 31 (28.97) | 13 (26.53) | 18 (31.03) | 0.60 |
Type of immunosuppressants used by patients under cared | ||||
Corticosteroids | 91 (85.04) | 41 (83.67) | 50 (86.20) | 0.81 |
Azathioprine | 45 (42.05) | 24 (48.97) | 21 (36.20) | 0.14 |
Methotrexate | 85 (79.43) | 40 (81.63) | 45 (77.58) | 0.37 |
Cyclophosphamide | 22 (20.56) | 13 (26.53) | 9 (15.51) | 0.14 |
Did not know the name of the drug | 10 (9.34) | 5 (10.20) | 5 (8.62) | 0.77 |